http://www.angletechnology.com/

research note, acrobat reader needed

latest results 24/1/06

Gets people thinking doesnt it....Actually like the charts here - but the other thread title is a bit more catchy lol

Okay consensus to keep this one and ditch the other one frpm now on.

For Immediate Release 4 May 2006


ANGLE plc

('ANGLE' or 'the Company')

New Venture Company: Parsortix Inc

ANGLE plc ('ANGLE'), the venture management and consulting company specialising
in the commercialisation of technology, is pleased to announce the launch of its
latest venture company, Parsortix Inc, which was agreed on 28 April but for
reasons of commercial confidentiality was embargoed until now.

In accordance with ANGLE's Progeny(R) process for creating new ventures,
Parsortix has secured intellectual property that has the potential to change the
$600 million global market for prenatal diagnostics by eliminating the need for
maternal invasive procedures. The technology, developed in private laboratories
in both the US and Europe, is also applicable to bone marrow transplant
procedures used in the therapeutic regimen for the treatment of cancer.

Approximately 6.5 million pregnancies occur in the United States alone each
year. Parsortix's technology enables the determination of chromosomal
abnormalities in the first trimester of pregnancy without the need for invasive
diagnostic procedures. Early definitive diagnosis for chromosomal abnormalities
associated with spina bifida, Down's, Turner, and Klinefelter syndromes, as well
as other disorders due to genetic abnormalities, can help physicians better care
for both the mother and the foetus during pregnancy. It also gives families
earlier information with respect to the health of the unborn child and avoids
the risk to mother and foetus of the maternal invasive procedures currently
used.

This technology should also help provide better care for chemotherapy and
radiation treated patients who have to undergo bone marrow transplants. In
addition, it should help ensure the safety of marrow transplants for the
patients receiving their own bone marrow (autologous transplants) and may also
be used in preventing immune rejection during bone marrow transplant from
another donor.

The technology will fit into current medical practice enabling less expensive
procedures, and more timely diagnosis adding value to both prenatal care and
cancer therapeutics.

In accordance with its process for new venture creation, ANGLE will provide
management and initial funding to Parsortix, creating a business plan, initial
management, IP protection, regulatory guidance, and product planning. This
company is being formed in accordance with the strategic relationship between
the Ben Franklin Technology Partners of Southeastern Pennsylvania and ANGLE.
The agreement provides that ANGLE will work with BFTP to form companies in the
South Eastern Pennsylvania region to promote economic development in the region
through the formation of technology based enterprises.

Commenting on the formation of Parsortix, ANGLE's Chief Executive, Andrew
Newland said:

'We are delighted to have launched Parsortix Inc. The prenatal diagnostic
market is one that is ready for a new approach and the benefits of early
diagnosis without the risk of maternal invasive procedures is enormous.

This is the first company resulting from our preferred commercialisation partner
agreement with Ben Franklin Technology Partners of Southeastern Pennsylvania
(BFTP/SEP), which provides ANGLE access to commercialisation opportunities from
more than $1 billion of research funding per annum in the Greater Philadelphia
region.'

annuver new venture for angle ......

Angle PLC
17 May 2006



For Immediate Release 17 May 2006


ANGLE plc
('ANGLE' or 'the Company')

New Venture Company: Kaloptics, Inc.

ANGLE plc ('ANGLE'), the venture management and consulting company specialising
in the commercialisation of technology, is pleased to announce that it has signed
an agreement with New York University (NYU) to commercialise innovative technology
developed at the Media Research Lab in the Computer Science Department of NYU's
Courant Institute of Mathematical Sciences. The agreement was effective on 30
April but for reasons of commercial confidentiality was embargoed until now.


Researchers Ken Perlin, PhD and Jeff Han have developed a patent-pending
kaleidoscope and software system that enables the rapid capture and recreation
of photo-realistic surface images. The technology has a wide range of commercial
applications in multi-billion dollar industries, including special effects,
animation, computer gaming and medical devices.


As part of its normal model for venture creation, ANGLE has formed and will
incubate Kaloptics, Inc. to lead the technology commercialisation, market and IP
assessment, and business strategy. ANGLE will contribute the initial management
of Kaloptics and lead a seed financing round for the company.


Ken Perlin is a professor in the Department of Computer Science at NYU and was
founding director of its Media Research Lab. His research interests include
graphics, animation, user interfaces and multimedia. He also received an Academy
Award for Technical Achievement from the Academy of Motion Picture Arts and
Sciences.


Jeff Han, a computer science researcher at NYU, has been working in the fields
of real-time computer graphics, computer vision, human-computer interfaces and
machine learning for over ten years.



ANGLE's Chief Executive, Andrew Newland, said:


'We are delighted to be working with New York University and its Media Research
Lab. These are world-class researchers who have produced numerous contributions
to their fields. We believe that the Kaleidoscope system can address a major
issue in multiple markets - the cost effective acquisition of data that can be
used for the creation of realistic surface images.'

Yes - looking good from here - overhang cleared with those large trades last week with 200k @ 77p.

Be nice to see some continued newsflow on their existing progency companies.

Expecting updates on 'Aberro' revenues via their release of STARwest - which were expected to be generated Q1 2006, as well as information on further product launches from 'Acolyte Biomedia' which were due in teh first half 2006 and teh possibility of a game industry deal from 'Geomerics' which was hinted at as well in teh first half 2006.